Sharon Wilks, Benedito Carneiro, Gregory Cote, Jason Henry, Shiraj Sen, Alexander I Spira, Frank Yung-Chin Tsai, Judy S Wang, Marsha Crochiere, Shui He, Sondra Smyrnios, Dipali Unadkat, Bin Zhang, Anthony W Tolcher
{"title":"762一项针对晚期实体瘤患者的EDB+FN靶向ADC PYX-201的安全性、耐受性、药代动力学、药效学和疗效的人体i期临床研究","authors":"Sharon Wilks, Benedito Carneiro, Gregory Cote, Jason Henry, Shiraj Sen, Alexander I Spira, Frank Yung-Chin Tsai, Judy S Wang, Marsha Crochiere, Shui He, Sondra Smyrnios, Dipali Unadkat, Bin Zhang, Anthony W Tolcher","doi":"10.1136/jitc-2023-sitc2023.0762","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":500964,"journal":{"name":"Regular and Young Investigator Award Abstracts","volume":"202 2","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors\",\"authors\":\"Sharon Wilks, Benedito Carneiro, Gregory Cote, Jason Henry, Shiraj Sen, Alexander I Spira, Frank Yung-Chin Tsai, Judy S Wang, Marsha Crochiere, Shui He, Sondra Smyrnios, Dipali Unadkat, Bin Zhang, Anthony W Tolcher\",\"doi\":\"10.1136/jitc-2023-sitc2023.0762\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":500964,\"journal\":{\"name\":\"Regular and Young Investigator Award Abstracts\",\"volume\":\"202 2\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Regular and Young Investigator Award Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jitc-2023-sitc2023.0762\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regular and Young Investigator Award Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jitc-2023-sitc2023.0762","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors